Background: Molecular targeted therapy (MTT) is an established treatment for patients with metastatic colorectal cancer. However, its role as neoadjuvant therapy in curative resection of colorectal liver metastases (CLM) remains controversial. The new EPOC study has raised further questions regarding the use of MTT for operable liver metastases. Methods: Patients undergoing surgical resection with curative intent for CLM treated with or without neoadjuvant therapy including molecular targeted therapy were included in this study. Patient characteristics and survival outcomes were analysed. Results: Between 2008 to 2013, 60 patients from a single institution who underwent resection of CLM with curative intent, were analysed. Median age was 62. 35 patients had preoperative chemotherapy, of which 18 had MTT. 48 patients had postoperative chemotherapy, 12 combined with MTT. Objective response rate was achieved in 26 (74%) of patients receiving neoadjuvant therapy. Pathological complete response was achieved in 6 patients (10%). 44 out of 60 patients (73%) were alive and 27 patients (45%) were disease free at time of analysis. Patients who had post operative MTT had a worse PFS than those who did not (HR 5.43, 95%CI: 1.07-27.47). Effects of pre operative chemotherapy, pre operative MTT and post operative chemotherapy were variable (HR 1.62, 95%CI: 0.58-4.58; HR 2.00, 95% CI: 0.63-6.33; HR 1.18, 95%CI: 0.61-5.38). Presence of more than 4 liver metastases on initial assessment conferred a poorer PFS (HR 4.2, 95%CI: 1.35-13.09). Pre-operative CEA was not prognostic (HR 1.00, 95%CI: 0.99-1.01). Of those who progressed, median PFS was 15.9 months. Conclusion: Adjuvant systemic therapy is standard of care in the management of CLM. The optimal incorporation of MTT is yet to be established. This single institution series shows a detrimental effect with the addition of postoperative MTT.